Zoetis (ZTS) Cash from Operations (2012 - 2026)
Zoetis' (ZTS) quarterly Cash from Operations came in at $655.0 million in Q2 2026, up 8.26% year-over-year from $605.0 million in Q2 2025, and up 63.34% quarter-over-quarter from $401.0 million in Q1 2026.
Analysis
Zoetis (ZTS) Cash from Operations (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has reported Cash from Operations for 15 consecutive years, with $655.0 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Cash from Operations rose 8.26% year-over-year to $655.0 million in Q2 2026; TTM through Jun 2026 was $2.8 billion, a 4.57% decrease from a year earlier, with the FY2025 full-year figure at $2.9 billion, down 1.66% from the prior year.
- Cash from Operations was $655.0 million for Q2 2026 at Zoetis, up from $401.0 million in the prior quarter.
- Over five years, Cash from Operations peaked at $951.0 million in Q3 2024 and troughed at $183.0 million in Q2 2023.
- A 5-year average of $621.0 million and a median of $600.0 million in 2024 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations slumped 45.54% in 2023 and soared 174.32% in 2024, its largest moves.
- Over 5 years, Cash from Operations stood at $741.0 million in 2022, then advanced by 21.05% to $897.0 million in 2023, then advanced by 0.89% to $905.0 million in 2024, then decreased by 1.33% to $893.0 million in 2025, then decreased by 26.65% to $655.0 million in 2026.
- The last three Cash from Operations figures came in at $655.0 million (Q2 2026), $401.0 million (Q1 2026), and $893.0 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Idexx Laboratories | 40.69 Bn | 40.49 Bn | 779.09 Mn | 347.16 Mn |
| 2 | Zoetis | 30.63 Bn | 28.95 Bn | 1.05 Bn | 655.00 Mn |
| 3 | Elanco Animal Health | 11.77 Bn | 11.24 Bn | 798.00 Mn | 277.00 Mn |
| 4 | Phibro Animal Health | 1.49 Bn | 1.41 Bn | 134.40 Mn | 24.09 Mn |
| 5 | Immucell | 90.19 Mn | 81.33 Mn | 2.44 Mn | - |
| 6 | Zhengye Biotechnology Holding | 76.23 Mn | 69.14 Mn | - | - |
| 7 | Global Innovative Platforms | 24.88 Mn | 24.63 Mn | - | -133,565.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 655.00 Mn |
| Mar 31, 2026 | 401.00 Mn |
| Dec 31, 2025 | 893.00 Mn |
| Sep 30, 2025 | 891.00 Mn |
| Jun 30, 2025 | 605.00 Mn |
| Mar 31, 2025 | 515.00 Mn |
| Dec 31, 2024 | 905.00 Mn |
| Sep 30, 2024 | 951.00 Mn |
| Jun 30, 2024 | 502.00 Mn |
| Mar 31, 2024 | 595.00 Mn |
| Dec 31, 2023 | 897.00 Mn |
| Sep 30, 2023 | 724.00 Mn |
| Jun 30, 2023 | 183.00 Mn |
| Mar 31, 2023 | 549.00 Mn |
| Dec 31, 2022 | 741.00 Mn |
| Sep 30, 2022 | 526.00 Mn |
| Jun 30, 2022 | 336.00 Mn |
| Mar 31, 2022 | 309.00 Mn |
| Dec 31, 2021 | 679.00 Mn |
| Sep 30, 2021 | 653.00 Mn |